COGNITION THERAPEUTICS INC (CGTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US19243B1026
COGNITION THERAPEUTICS INC financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -47.80 m USD |
| EBIT | -23.49 m USD |
| Net income | -23.49 m USD |
| Diluted EPS – continuing operations | -0.32 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About COGNITION THERAPEUTICS INC
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
More stocks
- Morefield Group N.V. (MORE.AS)
- JUPITER NEUROSCIENCES, INC. (JUNS)
- Strong H Machinery Technology (Cayman) Incorporation (4560.TW)
- Gseven Co Ltd (2937.TWO)
- T&R Biofab Co. Ltd (246710.KQ)
- CHAMPIONS ONCOLOGY, INC. (CSBR)
- Integrated Solutions Technology, Inc. (6927.TWO)
- Pluk Phak Praw Rak Mae Public Company Limited (OKJ.BK)
- Datavan International (3521.TWO)
- SOLESENCE, INC. (SLSN)
- ALPHA PRO TECH LTD (APT)
- Sun Brothers Development Co Ltd (3489.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.